USPTO Examiner ALLEY GENEVIEVE S - Art Unit 1617

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19205510ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFRMay 2025June 2025Allow100YesNo
18809240COMPOSITIONS FOR THE EFFECTIVE TREATMENT OF VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONSAugust 2024March 2026Allow1931YesNo
18795731COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795711COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18795683COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2024October 2024Allow200YesNo
18758007COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAJune 2024December 2024Allow610NoNo
18752293LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOFJune 2024January 2026Allow1930NoNo
18606407STABLE CHLORINATED ALKALINE PRODUCTSMarch 2024March 2026Allow2410YesNo
18692195POROUS AEROGEL SCAFFOLD, METHOD OF PREPARING THE SAME AND USE THEREOFMarch 2024August 2025Allow1700YesNo
18444485Compositions comprising pharmaceutically acceptable salts of amylin analogs and uses thereofFebruary 2024April 2025Allow1421NoNo
18443689NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSFebruary 2024May 2024Allow300YesNo
18430003NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSFebruary 2024January 2025Abandon1110NoNo
18421405LOSARTAN LIQUID FORMULATIONS AND METHODS OF USEJanuary 2024July 2024Allow610YesNo
18367542MONOGLYCEROL ACRYLATE BASED POLYMER AND USES THEREOFDecember 2023March 2026Allow3001YesNo
18518100COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023February 2024Allow310NoNo
18518093COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023April 2024Allow410NoNo
18518110COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREANovember 2023March 2024Allow400YesNo
18385915METHOD FOR PREPARING NANO-IMMUNE ACTIVATOR, ARTICLE AND USE THEREOFNovember 2023February 2026Allow2811NoNo
18498553PHARMACEUTICAL COMPOSITIONS COMPRISING SORBITAN ESTERSOctober 2023January 2026Allow2710YesNo
18558335LIPID COMPOUND AND USE THEREOF IN DELIVERY OF NUCLEIC ACIDOctober 2023October 2025Allow2401NoNo
18490188COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAOctober 2023January 2024Allow300YesNo
18490197COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAOctober 2023January 2024Allow200YesNo
18470280COMPOSITIONS AND METHODS FOR TARGETED RNA DELIVERYSeptember 2023December 2024Allow1421NoNo
18462956Taxane Analogs for the Treatment of Brain CancerSeptember 2023February 2026Allow2910YesNo
18448347COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2023October 2023Allow200YesNo
18448309COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2023October 2023Allow200YesNo
18448312COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2023January 2024Allow500YesNo
18448333COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHEYL)-3-PHENYLUREAAugust 2023September 2023Allow200YesNo
18229728ALUMINOSILICATE GLASS WITH PHOSPHORUS AND POTASSIUMAugust 2023June 2024Allow1121NoYes
18363641INSECTICIDAL TABLET COMPOSITIONSAugust 2023December 2025Allow2851YesYes
18361981Dendritic Macroporous Hydrogels Prepared By Crystal TemplatingJuly 2023March 2024Allow710NoNo
18216890NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSJune 2023February 2024Allow710YesNo
18346015GAMMA-HYDROXYBUTYRATE COMPOSITIONS AND THEIR USES FOR THE TREATMENT OF DISORDERSJune 2023March 2026Abandon3210NoNo
18211834Hygiene Product Pod and Methods of Using SameJune 2023January 2026Allow3120YesNo
18144800ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFRMay 2023February 2025Allow2110YesNo
18251929COMPOSITION FOR TREATING AND/OR PREVENTING FUNGAL INFECTIONSMay 2023December 2023Allow710YesNo
18032493NANOPARTICLES FOR USE IN ANTI PATHOGENIC APPLICATIONSApril 2023March 2026Abandon3501NoNo
18297698TOPICAL PHOSPHOINOSITIDE 3-KINASE INHIBITORSApril 2023September 2025Allow2910NoNo
18187878Targeting MicrobubblesMarch 2023July 2025Allow2810NoNo
18246151COMPOSITIONS COMPRISING REACTION PRODUCTS OF SACCHARIDE POLYMERS AND FATTY ESTERS FORMULATED WITH A NEUTRAL SURFACTANTMarch 2023December 2023Allow910YesNo
18178789COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREAMarch 2023July 2023Allow510YesNo
18044015USE, IN AQUEOUS-ALCOHOLIC COMPOSITIONS, OF A COPOLYMER OBTAINED BY PRECIPITATION POLYMERIZATIONMarch 2023March 2025Abandon2430YesNo
18170185LAMOTRIGINE ORAL LIQUID SUSPENSION AND USE THEREOFFebruary 2023January 2026Allow3530NoNo
18040496USE OF CASPASE INHIBITOR FOR ALLEVIATING OR TREATING OSTEOARTHRITISFebruary 2023January 2026Abandon3610NoNo
18161264EXTENDED RELEASE LIQUID COMPOSITIONS OF GUAIFENESINJanuary 2023September 2025Abandon3210NoNo
18151846ONAPRISTONE EXTENDED-RELEASE COMPOSITIONS AND METHODSJanuary 2023November 2023Abandon1010NoNo
18094050AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFJanuary 2023March 2024Allow1430YesNo
18148766COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREADecember 2022June 2023Allow510NoNo
18090582AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFDecember 2022February 2024Allow1330YesNo
18089338AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFDecember 2022February 2024Allow1430YesNo
18083253Seed Treatment Methods and CompositionsDecember 2022November 2025Allow3510NoNo
18064222METHODS OF EFFICIENTLY TREATING VITAMIN C DEFICIENCY-RELATED DISEASES AND OTHER CONDITIONSDecember 2022May 2024Allow1730YesNo
18061819LOSARTAN LIQUID FORMULATIONS AND METHODS OF USEDecember 2022February 2026Allow3830YesNo
17993422NON-SEDATING DEXMEDETOMIDINE TREATMENT REGIMENSNovember 2022November 2023Allow1120YesNo
17998998COMPOUNDS AS PROTEIN KINASE INHIBITORSNovember 2022December 2025Abandon3710YesNo
17998895PARTICLE CONTAINING LIPID NANOPARTICLES AND METHOD FOR PRODUCING SAMENovember 2022August 2025Allow3320YesNo
18052116LOSARTAN LIQUID FORMULATIONS AND METHODS OF USENovember 2022December 2023Allow1321YesNo
18050951METHOD OF MANUFACTURING ANTIFOULING COATING POLYMER USING INITIATED CHEMICAL VAPOR DEPOSITIONOctober 2022May 2025Allow3120NoNo
18047964PROCESS FOR MESALAZINE SOLID FORMULATIONSOctober 2022October 2024Allow2410YesNo
18046778METHOD OF PREPARING NANOPARTICLES BY HOT-MELT EXTRUSIONOctober 2022December 2024Allow2620NoNo
17965633STABILIZING VITAMIN C TOPICAL FORMULATIONSOctober 2022June 2025Allow3241YesNo
17961205STABILIZATION OF RNA FOR EXOGENOUS RNAi AGRICULTURAL APPLICATIONS AND FORMULATIONSOctober 2022October 2025Allow3641YesNo
17995053FORMULATIONSeptember 2022November 2025Abandon3801NoNo
17932453OPHTHALMIC FORMULATIONS OF METHOTREXATESeptember 2022March 2024Allow1821YesNo
17932426OPHTHALMIC FORMULATIONS OF METHOTREXATESeptember 2022March 2024Allow1821YesNo
17900953ANTIMICROBIAL GLASS COMPOSITIONS, GLASSES AND POLYMERIC ARTICLES INCORPORATING THE SAMESeptember 2022March 2025Abandon3110NoNo
17816486VALPROIC ACID FOR THE TREATMENT OR PREVENTION OF PATHOLOGICAL CONDITIONS ASSOCIATED WITH EXCESS FIBRIN DEPOSITION AND/OR THROMBUS FORMATIONAugust 2022December 2024Allow2910NoNo
17759568METHODS OF CONTROLLING OR PREVENTING PANAMA DISEASE IN BANANA PLANTSJuly 2022January 2026Allow4201NoNo
17815045HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODSJuly 2022March 2026Abandon4320NoYes
17759385COMPOSITIONS AND METHODS FOR THE IMPROVEMENT AND MAINTENANCE OF GLUCOSE METABOLISM IN CHILDHOOD AND ADOLESCENCEJuly 2022December 2025Abandon4110NoNo
17866939AMORPHOUS NILOTINIB MICROPARTICLES AND USES THEREOFJuly 2022February 2024Allow1941YesNo
17862421METHOD FOR PREPARING PEI-LIPID NANOPARTICLES USED FOR DELIVERING A MRNA VACCINE AND TRANSFECTING STEM CELLSJuly 2022October 2024Allow2710NoNo
17810934Protection of Polyunsaturated Fatty Acids from Ruminal DegradationJuly 2022October 2025Allow3901YesNo
17790808SOLUBLE MELATONIN TRIPARTATE ADDUCT FOR THE PREVENTION AND TREATMENT OF RARE AND SEVERE EYE SIGHT-THREATENING CONDITIONS AND NEURO-OPHTHALMIC DISORDERSJuly 2022March 2023Allow910YesNo
17788895ANTI-AGING COSMETIC COMPOSITION BASED ON RESVERATROL AND MAGNOLIAJune 2022December 2025Abandon4220YesNo
17843769ISOINDOLINONE AND INDAZOLE COMPOUNDS FOR THE DEGRADATION OF EGFRJune 2022December 2022Allow600NoNo
17840287Onychomycosis Treatment Compositions and MethodsJune 2022December 2025Allow4211YesNo
17838364HAIR CARE COMPOSITIONS COMPRISING HYDROXYLATED TRIGLYCERIDE OLIGOMERSJune 2022May 2024Allow2320YesNo
17744932EXTENDED-RELEASE DRUG DELIVERY COMPOSITIONSMay 2022March 2026Abandon4650YesNo
17743679METHODS OF MODULATING IMMUNE ACTIVITYMay 2022February 2026Abandon4501NoNo
17774922COMPOSITION CONTAINING LEVAMLODIPINE BESYLATE HYDRATE AND ITS PREPARATION METHODMay 2022February 2026Allow4520NoNo
17774845COMPOSITION WITH SUPERABSORBENT POLYMERMay 2022May 2025Allow3610YesNo
17774229COMPOSITIONS AND METHODS FOR DELIVERING CANNABINOIDS TO SKINMay 2022January 2026Abandon4510NoNo
17735820COMPOSITIONS OF 1-(4-BROMO-5-(1-ETHYL-7-(METHYLAMINO)-2-OXO-1,2-DIHYDRO-1,6-NAPHTHYRIDIN-3-YL)-2-FLUOROPHENYL)-3-PHENYLUREAMay 2022December 2022Allow710YesNo
17773995PYRIDYLOXYACETIC ACID COMPOUND AND USE OF SAMEMay 2022May 2025Allow3611YesNo
17734420ESLICARBAZEPINE SUSPENSIONMay 2022January 2026Abandon4510NoNo
17722688ALUMINOSILICATE GLASS WITH PHOSPHORUS AND POTASSIUMApril 2022April 2023Allow1221YesYes
17715355PHOTOPROTECTIVE COMPOSITIONS COMPRISING A DIBENZOYLMETHANE DERIVATIVE, A MEROCYANINE COMPOUND AND A COMPOUND CAPABLE OF ACCEPTING THE TRIPLET EXCITED LEVEL ENERGY OF THE DIBENZOYLMETHANE COMPOUNDApril 2022November 2023Abandon1910NoNo
17712742Onychomycosis Treatment MethodsApril 2022November 2025Allow4320YesNo
17655615BOWEL CLEANSING CHEMICAL COMPOSITION AND ASSOCIATED USE THEREFOREMarch 2022July 2025Allow4000YesNo
17692521SOFT GELATIN CAPSULES CONTAINING A MIXTURE OF ANALGESICS AND DECONGESTANTS, EXPECTORANTS, ANTITUSSIVES AND/OR ANTIHISTAMINESMarch 2022May 2023Allow1400YesNo
17753721OPHTHALMIC FORMULATIONS OF METHOTREXATEMarch 2022January 2026Allow4620NoNo
17686373SUSPENSION COMPONENT-SPECIFIC TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USEMarch 2022April 2022Allow100YesNo
17686371LIMITED PARTICLE SIZE TRIAMCINOLONE AND MOXIFLOXACIN COMPOSITIONS AND ASSOCIATED METHODS OF USEMarch 2022May 2022Allow200YesNo
17686368MOXIFLOXACIN AND TRIAMCINOLONE COMPOSITIONS AND ASSOCIATED METHODSMarch 2022April 2022Allow100YesNo
17673504BIODEGRADABLE EXTENDED RELEASE MICROSPHERE-HYDROGEL OCULAR DRUG DELIVERY SYSTEM AND METHODFebruary 2022December 2025Allow4611NoNo
17592700Choline EstersFebruary 2022March 2025Abandon3710NoNo
17591250INDANE DERIVATIVES FOR MALODOR COUNTERACTIONFebruary 2022November 2024Abandon3411NoNo
17590213Vaginal HydrogelFebruary 2022August 2023Allow1810YesNo
17584997ANTI-AGING DRUG COMBINATION AND USE THEREOFJanuary 2022September 2024Allow3211YesNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner ALLEY, GENEVIEVE S.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
21
Examiner Affirmed
19
(90.5%)
Examiner Reversed
2
(9.5%)
Reversal Percentile
23.1%
Lower than average

What This Means

With a 9.5% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is in the bottom 25% across the USPTO, indicating that appeals face significant challenges here.

Strategic Value of Filing an Appeal

Total Appeal Filings
72
Allowed After Appeal Filing
21
(29.2%)
Not Allowed After Appeal Filing
51
(70.8%)
Filing Benefit Percentile
43.7%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 29.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner ALLEY, GENEVIEVE S - Prosecution Strategy Guide

Executive Summary

Examiner ALLEY, GENEVIEVE S works in Art Unit 1617 and has examined 705 patent applications in our dataset. With an allowance rate of 58.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 32 months.

Allowance Patterns

Examiner ALLEY, GENEVIEVE S's allowance rate of 58.3% places them in the 19% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by ALLEY, GENEVIEVE S receive 2.34 office actions before reaching final disposition. This places the examiner in the 66% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by ALLEY, GENEVIEVE S is 32 months. This places the examiner in the 49% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +54.0% benefit to allowance rate for applications examined by ALLEY, GENEVIEVE S. This interview benefit is in the 95% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 22.3% of applications are subsequently allowed. This success rate is in the 28% percentile among all examiners. Strategic Insight: RCEs show below-average effectiveness with this examiner. Carefully evaluate whether an RCE or continuation is the better strategy.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 28.9% of cases where such amendments are filed. This entry rate is in the 41% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 53.3% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 47% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 63.2% of appeals filed. This is in the 42% percentile among all examiners. Of these withdrawals, 52.8% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.

Petition Practice

When applicants file petitions regarding this examiner's actions, 64.4% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 0.1% of allowed cases (in the 50% percentile). This examiner makes examiner's amendments more often than average to place applications in condition for allowance (MPEP § 1302.04).

Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.